New Delhi, May 5 (IANS) Claire Mazumdar, a US-based biotech entrepreneur and CEO of a Nasdaq-listed firm, on Tuesday identified as the future successor to Kiran Mazumdar-Shaw at Biocon, marking a key step in the company’s long-term leadership transition.Kiran Mazumdar-Shaw, founder and chairperson of Biocon, said she has formally charted a succession plan and chosen her niece Claire to eventually take over the reins of the company. She noted that as the sole owner of Biocon, it was important t…
Latest Biocon News & Updates
New Delhi, May 5 (IANS) Biocon founder Kiran Mazumdar-Shaw has named her niece Claire Mazumdar as her successor, outlining a formal succession plan for the biopharmaceutical company, according to a report.In an interview with Fortune India, Mazumdar-Shaw (73) said she sees Claire (37) as the right person to lead Biocon, a leading biopharmaceutical firm, into its next phase of growth.“I am the sole owner of Biocon, and I need to make sure that I put it in good hands. I have seen my niece Claire…
Washington, March 4 (IANS) The U.S. International Trade Commission (USITC) has received a complaint alleging that biosimilar versions of the cancer drug pertuzumab imported into the United States violate U.S. trade law. Several entities of India’s largest biopharmaceutical company, Biocon, have been named as respondents.The notice was published in the Federal Register. It said the complaint was filed by the world’s top biotech company, Genentech, on February 27, 2026.“The Commiss…
Bengaluru, Feb 18 (IANS) United States Under Secretary of Commerce for International Trade William Kimmitt led a delegation of officials from the International Trade Administration (ITA) to Bengaluru this week, marking the first leg of a visit to India ahead of the Department of Commerce’s participation in the 2026 India AI Impact Summit, according to an official statement from the US Consulate.The statement said that during the visit to Bengaluru on February 17, Kimmitt and the delegation met…
New Delhi, Dec 26 (IANS) From changing the definition to the rise of GLP-1 medications, and the government’s several initiatives, especially Prime Minister Narendra Modi’s clarion call, obesity became the focus of healthcare in India in 2025.The anti-obesity drive, especially the generic drugs, will continue to remain a key focus in 2026.Traditionally, Body Mass Index (BMI) was used to define obesity, but after 15 long years, India revamped its obesity guidelines in 2025 by lowering the thresh…